Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Minocycline + hyaluronic acid is a **combination formulation** designed to deliver minocycline, a tetracycline-class antibiotic, with hyaluronic acid, a biocompatible polymer, typically in a hydrogel or gel system for localized therapy. This type of combination has been researched primarily in the context of **periodontitis treatment** and other localized biofilm-associated infections. - **Minocycline** acts by inhibiting bacterial protein synthesis, providing strong antimicrobial and anti-inflammatory effects. - **Hyaluronic acid** is used as a bioadhesive carrier, enhancing drug retention at the application site, supporting tissue regeneration, and providing a sustained release profile. - These hydrogels or gels can regulate immune responses, facilitate tissue repair, and restore epithelial barriers more efficiently than commercial products containing minocycline alone. - Such combinations are not widely marketed as a unique brand but represent an emerging class of localized drug delivery systems for dental and periodontal applications[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on minocycline + hyaluronic acid.